echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancers: Water-soluble SIGLEC5 (sSIGLEC5): A new prognostic indicator for colorectal cancer

    Cancers: Water-soluble SIGLEC5 (sSIGLEC5): A new prognostic indicator for colorectal cancer

    • Last Update: 2021-08-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Of colorectal cancer (CRC) is the world's common digestive tract
    .
    The clinical features, prognosis and response to treatment of colorectal cancer are different

    .
    Therefore, the left and right half of colorectal cancer are considered to be two diseases, which also shows that colorectal cancer is a highly heterogeneous disease

    .
    CEA has always been used for the auxiliary
    diagnosis and efficacy testing of colorectal cancer , but its specificity is not strong, and many tumors also have different degrees of increase
    .
    Therefore, it is urgent to find effective prognostic indicators

    .
    Research published in the journal Cancers shows that water-soluble SIGLEC5 (sSIGLEC5) is a new prognostic indicator for colorectal cancer

    .

    Of colorectal cancer (CRC) is the world's common digestive tract
    .
    The clinical features, prognosis and response to treatment of colorectal cancer are different

    .
    Therefore, the left and right half of colorectal cancer are considered to be two diseases, which also shows that colorectal cancer is a highly heterogeneous disease

    .
    CEA has always been used for the auxiliary
    diagnosis and efficacy detection of colorectal cancer , but its specificity is not strong, and many tumors also have different degrees of increase
    .
    Therefore, it is urgent to find effective prognostic indicators

    .
    Research published in the journal Cancers shows that water-soluble SIGLEC5 (sSIGLEC5) is a new prognostic indicator for colorectal cancer

    .
    Digestive diagnosis of colorectal cancer

    From May 28, 2015 to August 11, 2020, a total of 114 CRC patients and 67 healthy people were included in the study
    .
    Blood samples were collected 24 hours before the operation of CRC patients, and they were followed up until April 7, 2021

    .
    CRC patients were analyzed according to tumor stage (stage I, II, III, IV)

    .

    From May 28, 2015 to August 11, 2020, a total of 114 CRC patients and 67 healthy people were included in the study
    .
    Blood samples were collected 24 hours before the operation of CRC patients, and they were followed up until April 7, 2021

    .
    CRC patients were analyzed according to tumor stage (stage I, II, III, IV)

    .

    Compared with healthy people, the level of sSIGLEC5 in the plasma of CRC patients was significantly increased, with a statistical difference (p ≤ 0.
    0001), and the level of sSIGLEC5 in dead patients was also significantly higher than that in survivors

    .

    Compared with healthy people, the level of sSIGLEC5 in the plasma of CRC patients was significantly increased, with a statistical difference (p ≤ 0.
    0001), and the level of sSIGLEC5 in dead patients was also significantly higher than that in survivors

    .
    Compared with healthy people, the level of sSIGLEC5 in the plasma of CRC patients was significantly increased, with a statistical difference (p ≤ 0.
    0001), and the level of sSIGLEC5 in dead patients was also significantly higher than that in survivors

    .


    Comparison of the level of CRC and healthy people

    Comparison of the level of CRC and healthy people

    Then analyze the levels of sSIGLEC5 in patients with different stages, and it can be found that as the stage increases, the level of sSIGLEC5 is higher, and it is positively correlated with the stage of the patient (Pearson r = 0.
    2595, p = 0.
    005)

    .
    Similarly, the level of sSIGLEC5 is related to the patient's grade and lymph node invasion

    .

    Then analyze the levels of sSIGLEC5 in patients with different stages, and it can be found that as the stage increases, the level of sSIGLEC5 is higher, and it is positively correlated with the stage of the patient (Pearson r = 0.
    2595, p = 0.
    005)

    .
    Similarly, the level of sSIGLEC5 is related to the patient's grade and lymph node invasion

    .
    Then analyze the levels of sSIGLEC5 in patients with different stages, and it can be found that as the stage increases, the level of sSIGLEC5 is higher, and it is positively correlated with the stage of the patient (Pearson r = 0.
    2595, p = 0.
    005)

    .
    Similarly, the level of sSIGLEC5 is related to the patient's grade and lymph node invasion

    .


    Different stages and correlation analysis

    Different stages and correlation analysis

    In order to distinguish death and survival patients, the investigator performed ROC curve analysis, and the AUC was 0.
    853; 95% CI 0.
    7729–0.
    9344; there was a statistical difference (p = 0.
    0001)

    .
    The best decomposition value is 412.
    6 ng/mL, which shows high sensitivity (1; 95% CI 74.
    12–100) and specificity (0.
    67, 95% CI 57.
    31–75.
    44)

    .

    In order to distinguish death and survival patients, the investigator performed ROC curve analysis, and the AUC was 0.
    853; 95% CI 0.
    7729–0.
    9344; there was a statistical difference (p = 0.
    0001)

    .
    The best decomposition value is 412.
    6 ng/mL, which shows high sensitivity (1; 95% CI 74.
    12–100) and specificity (0.
    67, 95% CI 57.
    31–75.
    44)

    .
    In order to distinguish death and survival patients, the investigator performed ROC curve analysis, and the AUC was 0.
    853; 95% CI 0.
    7729–0.
    9344; there was a statistical difference (p = 0.
    0001)

    .
    The best decomposition value is 412.
    6 ng/mL, which shows high sensitivity (1; 95% CI 74.
    12–100) and specificity (0.
    67, 95% CI 57.
    31–75.
    44)

    .


    ROC

    ROC

    Wald regression model analyzes whether the following variables are independent prognostic factors: age, gender, stage, treatment, tumor size, lymph node metastasis, lymphatic invasion, nerve invasion, surgical margin, CEA, grade and sSIGLEC5
    .
    The study found that only grade and sSIGLEC5 were independent prognostic factors

    .

    Wald regression model analyzes whether the following variables are independent prognostic factors: age, gender, stage, treatment, tumor size, lymph node metastasis, lymphatic invasion, nerve invasion, surgical margin, CEA, grade and sSIGLEC5
    .
    The study found that only grade and sSIGLEC5 were independent prognostic factors

    .
    Wald regression model analyzes whether the following variables are independent prognostic factors: age, gender, stage, treatment, tumor size, lymph node metastasis, lymphatic invasion, nerve invasion, surgical margin, CEA, grade and sSIGLEC5
    .
    The study found that only grade and sSIGLEC5 were independent prognostic factors

    .


    Regression analysis of prognostic factors

    Regression analysis of prognostic factors

    Kaplan–Meier curve for survival analysis, the overall survival (OS) of patients with high levels of sSIGLEC5 and lower levels was significantly shortened (HR=15.
    68; 95% CI 4.
    571–53.
    81; p ≤ 0.
    0001)

    .


    subsistence analysis

    subsistence analysis

    In summary, the study shows that water-soluble SIGLEC5 (sSIGLEC5) is a prognostic indicator for patients with colorectal cancer
    .

    In summary, the study shows that water-soluble SIGLEC5 (sSIGLEC5) is a prognostic indicator for patients with colorectal cancer
    .
    This study shows that water-soluble SIGLEC5 (sSIGLEC5) is a prognostic indicator for patients with colorectal cancer
    .
    The study showed that water-soluble SIGLEC5 (sSIGLEC5) is a prognostic indicator for patients with colorectal cancer
    .

    Original source:

    Original source:

    Montalbán-Hernández, K.
    ; Cantero-Cid, R.
    ; Lozano-Rodríguez, R.
    ; et al.
    Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients.
    Cancers 2021, 13, 3896.
    https://doi.
    org /10.
    3390/cancers13153896.

    Montalbán-Hernández, K.
    ; Cantero-Cid, R.
    ; Lozano-Rodríguez, R.
    ; et al.
    Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients.
    Cancers 2021, 13, 3896.
    https://doi.
    org /10.
    3390/cancers13153896.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.